高危III期黑色素瘤切除术后辅助帕博利珠单抗的健康相关生活质量结果
BACKGROUND: The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 trial in patients with resected, high-risk stage III melanoma demonstrated improved recurrence-free survival with adjuvant pembrolizumab compared with placebo (hazard ratio 0·57…
要点
- 结果支持在高危III期黑色素瘤切除术后使用辅助帕博利珠单抗。
核心结论
- 帕博利珠单抗作为切除的高危III期黑色素瘤辅助治疗,与安慰剂相比未导致临床显著的健康相关生活质量下降。
- 这些结果支持在该情况下使用辅助帕博利珠单抗。
研究设计与样本
- 欧洲癌症研究与治疗组织(EORTC)1325-MG/KEYNOTE-054试验为双盲、随机、对照、III期试验,在23个国家123个学术中心和社区医院进行。
- 纳入1019例既往未治疗、组织学确认的IIIA、IIIB或IIIC期切除皮肤黑色素瘤患者,ECOG体能状态评分为0或1,随机1:1分配接受帕博利珠单抗200 mg或安慰剂静脉给药,每3周一次,持续1年。
- 健康相关生活质量为预设探索性终点,主要分析为2年内通过EORTC QLQ-C30测量的总体健康/生活质量(GHQ),在意向治疗人群中分析。
主要发现
- 这些差异均在QLQ-C30的5分临床相关阈值内,因此临床非显著。
关键数值与推荐
- HRQOL依从性在基线时大于90%,第一年内大于70%,此后两组均大于60%;因后期绝对依从数低,分析截尾至第84周。
- QLQ-C30的临床相关阈值定义为5分。
临床怎么用
- 对于切除的高危III期黑色素瘤患者,辅助帕博利珠单抗不会临床显著降低健康相关生活质量,支持其临床应用。
局限性
- 因后期随访绝对依从数低,HRQOL分析截尾至第84周。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 trial in patients with resected, high-risk stage III melanoma demonstrated improved recurrence-free survival with adjuvant pembrolizumab compared with placebo (hazard ratio 0·57 [98·4% CI 0·43-0·74]; p<0·0001). This study reports the results from the health-related quality-of-life (HRQOL) exploratory endpoint. METHODS: This double-blind, randomised, controlled, phase 3 trial was done at 123 academic centres and community hospitals across 23 countries. Patients aged 18 years or older with previously untreated histologically confirmed stage IIIA, IIIB, or IIIC resected cutaneous melanoma, and an Eastern Cooperative Oncology Group performance status score of 1 or 0 were eligible. Patients were randomly assigned (1:1) using a central interactive voice-response system on the basis of a minimisation technique stratified for stage and geographic region to receive intravenously 200 mg pembrolizumab or placebo. Treatment was administered every 3 weeks for 1 year, or until disease recurrence, unacceptable toxicity, or death. The primary endpoint of the trial was recurrence-free survival (reported elsewhere). HRQOL was a prespecified exploratory endpoint, with global health/quality of life (GHQ) over 2 years measured by the EORTC QLQ-C30 as the primary analysis. Analyses were done in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT02362594, and EudraCT, 2014-004944-37, and long-term follow-up is ongoing. FINDINGS: Between Aug 26, 2015, and Nov 14, 2016, 1019 patients were assigned to pembrolizumab (n=514) or placebo (n=505). Median follow-up was 15·1 months (IQR 12·8-16·9) at the time of this analysis. HRQOL compliance was greater than 90% at baseline, greater than 70% during the first year, and greater than 60% thereafter for both groups. Because of low absolute compliance numbers at later follow-up, the analysis was truncated to week 84. Baseline GHQ scores were similar between groups (77·55 [SD 18·20] in the pembrolizumab group and 76·54 [17·81] in the placebo group) and remained stable over time. The difference in average GHQ score between the two groups over the 2 years was -2·2 points (95% CI -4·3 to -0·2). The difference in average score during treatment was -1·1 points (95% CI -3·2 to 0·9) and the difference in average score after treatment was -2·2 points (-4·8 to 0·4). These differences are within the 5-point clinical relevance threshold for the QLQ-C30 and are therefore clinically non-significant. INTERPRETATION: Pembrolizumab does not result in a clinically significant decrease in HRQOL compared with placebo when given as adjuvant therapy for patients with resected, high-risk stage III melanoma. These results support the use of adjuvant pembrolizumab in this setting. FUNDING: Merck Sharp & Dohme.
引用
- Bottomley A, Coens C, Mierzynska J, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021. PMID: 33857414. doi:10.1016/S1470-2045(21)00081-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。